Vivacelle Bio, Inc.

505(b)2-Ph3 clinical stage company focused on treating septic shock, multiple organ dysfunction syndrome, hemorrhagic shock & reperfusion injury by addressing conditions related to lack of blood supply including absolute hypovolemia & relative hypovolemia